The global brachytherapy market size was exhibited at USD 908.78 million in 2023 and is projected to hit around USD 1,806.17 million by 2033, growing at a CAGR of 7.11% during the forecast period of 2024 to 2033.
Key Takeaways:
Brachytherapy Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 973.39 Million |
| Market Size by 2033 | USD 1,806.17 Million |
| Growth Rate From 2024 to 2033 | CAGR of 7.11% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Product, Dosage Type, Application, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Varian Medical Systems, Inc.; Becton, Dickinson & Company; Elekta AB; Isoray Medical, Inc.; Eckert & Ziegler BEBIG; iCAD, Inc.; CIVCO Medical Solutions; Theragenics Corporation |
The increasing prevalence of cancer, technological advancements, and a significant rise in the adoption of brachytherapy are expected to drive the growth of the market during the forecast period. Brachytherapy is a type of radiation therapy used for the treatment of cancer. The radioactive materials are placed inside the body with the help of catheters. It is an excellent treatment for localized tumors. Currently, artificially produced radionuclides such as Caesium-137, Iridium-192, Gold-198, Iodine-125, and Palladium-103 are routinely used.
According to the American Cancer Society, in the U.S., there were 609,360 cancer deaths and an estimated 1.9 million new cancer cases in 2023. This is expected to increase to 24.6 million by 2030. The increasing cancer burden is one of the major factors driving market growth.
Radiation therapy can be used for prophylactic, palliative, or curative treatment. It can also be used as monotherapy or as an adjuvant with surgery, immunotherapy, and chemotherapy. The wide range of applications of radiotherapy has increased its adoption by physicians. The latest advancements in radiation therapy allow the delivery of a high amount of dose to the target area with minimum damage to nearby healthy tissues. This has increased the chances of localized tumor control and has improved cure rates, leading to an increase in demand for radiation therapy.
However, the lack of skilled radiotherapy professionals and access to technologically advanced products, particularly in developing countries is expected to be a major restraining factor for this market. According to the IAEA’s Directory of Radiotherapy Centres (DIRAC), there are around 3300 brachytherapy systems installed across radiation therapy centers globally, as of 2020. Around 60% of the cancer cases occur in LMICs and 80% of patients in these countries lack access to treatment due to limited access to technologically advanced systems. Around 60%-80% of the radiotherapy needs are met in the European countries, however, in LMICs, only 3%–4% of the radiotherapy needs are met.
Segments Insights:
Product Insights
The applicators & afterloaders segment dominated the market for brachytherapy and accounted for the largest revenue share of 44.5% in 2023. Applicators are more effective than others and are minimally intrusive, granting them a high level of patient preference. The radioactive sources are transported to the treatment site by a device called an afterloader. During HDR brachytherapy, a single radioactive source is momentarily inserted inside the tumor and then expelled.
The electronic brachytherapy segment is expected to grow at a significant CAGR over the forecast period. This technique is suitable for treating skin lesions and enables radiation shielding, thereby eliminating the challenges associated with radioisotope handling. Various advantages of electronic brachytherapy such as no leakage of radiation in off-state, less shielding, low dose to organs at risk, and no radioactive waste make it a preferable treatment in the region. ELEKTA AB and Xoft, Inc. are some of the prominent companies in this market.
Recently, encouraging results have emerged from clinical trials for new products being developed in this domain. For instance, in August 2021, iCAD, Inc.’s Xoft Axxent Electronic Brachytherapy System for the treatment of recurrent glioblastoma showed significant improvements in the overall survival of patients who received this treatment.
Application Insights
The prostate cancer segment accounted for the largest revenue share of 32.91% of the market for brachytherapy in 2023. The prostate cancer brachytherapy industry is expected to grow at a lucrative rate due to various advantages over other types of treatments. These advantages include safely increasing the dose to the tumor while minimizing the dose to the surrounding organs such as the rectum, bladder, and urethra; shorter duration of treatment; faster recovery; minimal risk of side effects due to the accurate and precise delivery of radiation dose; and effective treatment for patients with prostate cancer recurrence.
The breast cancer segment is expected to grow at the fastest CAGR during the forecast period. Accelerated Partial Breast Irradiation (APBI) is an innovative method of radiation therapy, which is employed after a lumpectomy.Brachytherapy APBI includes two methods. The first method involves multicatheter brachytherapy and the second method involves a single catheter, which inflates into a balloon once placed inside the breast. The single catheter method is not prescribed for all breast cancer patients. Multicatheter brachytherapy offers great flexibility and is said to be the most targeted APBI treatment. The presence of a wide range of products & instruments, such as SagiNova and Breast CT/MR template set is expected to boost the breast cancer brachytherapy industry’s growth.
Dosage Type Insights
The High-Dose Rate (HDR) brachytherapy segment dominated the market and accounted for the largest revenue share of 72.5% in 2023. HDR brachytherapy is an outpatient procedure and can be used as a standalone treatment or after surgical removal of tumors. The pain-free treatment may require one session or multiple sessions depending on the type of cancer being treated. Eckert & Ziegler BEBIG, Varian Medical Systems, and ELEKTA AB are some of the prominent companies in the HDR brachytherapy industry.
Low-Dose Rate (LDR) brachytherapy is primarily used for the treatment of prostate cancer. The introduction of new products such as GammaTile for the treatment of brain cancer is expected to drive the growth of this segment. According to the recent technological advancements mentioned in a report published on Elsevier in May 2023, LDR brachytherapy has made it possible to administer precise doses and has excelled at treating aggressive prostate tumors.
Regional Insights
North America led the market for brachytherapy and accounted for the largest revenue share of 46.5% in 2023. Brachytherapy procedure offers various advantages over traditional methods including efficiency and safety of the treatment, hence, it is widely used in the North American region. Favorable regulatory and reimbursement scenario further supports regional growth. Additionally, the investment scenario has drastically changed in the region and companies are now investing in developing new products and collaborating with emerging companies to maintain their market share and presence.
In Asia Pacific, the market is estimated to witness the highest CAGR over the forecast period. The high disease burden and the rising awareness amongst the target population are some major factors responsible for the forecasted growth. In addition, limited access to technologically advanced cancer treatments offers various opportunities for the market players. Additionally, the launch of various brachytherapy systems in developing economies such as India is expected to impact the market positively. For instance, in November 2023, Medicover Hospitals launched Asia’s first TrueBeam Identify system. The system is also Telangana’s (an Indian state) first SGRT making treatment more accessible for patients.
Some of the prominent players in the Brachytherapy market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global brachytherapy market.
Dosage Type
Product
Application
By Region
Chapter 1. Brachytherapy Market: Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Dosage Type
1.1.1.2. Product
1.1.1.3. Application
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List of Abbreviations
Chapter 2. Brachytherapy Market: Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Dosage Type outlook
2.2.2. Product outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Brachytherapy Market: Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Industry Value Chain Analysis
3.2.1. Reimbursement framework
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. The increasing prevalence of cancer
3.3.1.2. Technological advancements
3.3.2. Market restraint analysis
3.3.2.1. Lack of skilled radiotherapy professionals
3.4. Brachytherapy Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.4.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Brachytherapy: Dosage Type Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. High-Dose Rate (HDR)
4.1.2. Low-Dose Rate (LDR)
4.2. Dosage Type Market Share, 2024 & 2033
4.3. Segment Dashboard
4.4. Global Brachytherapy Market by Dosage Type Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.5.1. High-Dose Rate (HDR)
4.5.1.1. HDR market estimates and forecast 2021 to 2033
4.5.2. Low-Dose Rate (LDR)
4.5.2.1. LDR market estimates and forecast 2021 to 2033
Chapter 5. Brachytherapy: Product Estimates & Trend Analysis
5.1. Product Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Global Brachytherapy Market by Material Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.4.1. Seeds
5.4.1.1. Seeds market estimates and forecast 2021 to 2033
5.4.2. Applicators & Afterloaders
5.4.2.1. Applicators & Afterloaders market estimates and forecast 2021 to 2033
5.4.3. Electronic brachytherapy
5.4.3.1. Electronic brachytherapy market estimates and forecast 2021 to 2033
Chapter 6. Brachytherapy: Application Estimates & Trend Analysis
6.1. Application Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Global Brachytherapy Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.4.1. Prostrate
6.4.1.1. Prostrate market estimates and forecast 2021 to 2033
6.4.2. Gynecological Cancer
6.4.2.1. Gynecological Cancer market estimates and forecast 2021 to 2033
6.4.3. Breast
6.4.3.1. Breast management market estimates and forecast 2021 to 2033
6.4.4. Others
6.4.4.1. Others market estimates and forecast 2021 to 2033
Chapter 7. Brachytherapy Market: Regional Estimates & Trend Analysis
7.1. Regional market share analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Regional Market Share and Leading Players, 2021
7.4.1. North America
7.4.2. Europe
7.4.3. Asia Pacific
7.4.4. Latin America
7.4.5. Middle East and Africa
7.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East and Africa
7.6. Market Size, & Forecasts, Volume and Trend Analysis, 2021 to 2033:
7.7. North America
7.7.1. SWOT Analysis
7.7.2. North America Market estimates and forecast, 2021 - 2033
7.7.3. U.S.
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Competitive Scenario
7.7.3.4. Regulatory Framework
7.7.3.5. U.S. Market estimates and forecast, 2021 - 2033
7.7.4. Canada
7.7.4.1. Key Country Dynamics
7.7.4.2. Target Disease Prevalence
7.7.4.3. Competitive Scenario
7.7.4.4. Regulatory Framework
7.7.4.5. Canada Market estimates and forecast, 2021 - 2033
7.8. Europe
7.8.1. SWOT Analysis
7.8.2. Europe Market estimates and forecast, 2021 - 2033
7.8.3. UK
7.8.3.1. Key Country Dynamics
7.8.3.2. Target Disease Prevalence
7.8.3.3. Competitive Scenario
7.8.3.4. Regulatory Framework
7.8.3.5. UK Market estimates and forecast, 2021 - 2033
7.8.4. Germany
7.8.4.1. Key Country Dynamics
7.8.4.2. Target Disease Prevalence
7.8.4.3. Competitive Scenario
7.8.4.4. Regulatory Framework
7.8.4.5. Germany Market estimates and forecast, 2021 - 2033
7.8.5. France
7.8.5.1. Key Country Dynamics
7.8.5.2. Target Disease Prevalence
7.8.5.3. Competitive Scenario
7.8.5.4. Regulatory Framework
7.8.5.5. France Market estimates and forecast, 2021 - 2033
7.8.6. Italy
7.8.6.1. Key Country Dynamics
7.8.6.2. Target Disease Prevalence
7.8.6.3. Competitive Scenario
7.8.6.4. Regulatory Framework
7.8.6.5. Italy Market estimates and forecast, 2021 - 2033
7.8.7. Spain
7.8.7.1. Key Country Dynamics
7.8.7.2. Target Disease Prevalence
7.8.7.3. Competitive Scenario
7.8.7.4. Regulatory Framework
7.8.7.5. Spain Market estimates and forecast, 2021 - 2033
7.8.8. Denmark
7.8.8.1. Key Country Dynamics
7.8.8.2. Target Disease Prevalence
7.8.8.3. Competitive Scenario
7.8.8.4. Regulatory Framework
7.8.8.5. Denmark Market estimates and forecast, 2021 - 2033
7.8.9. Sweden
7.8.9.1. Key Country Dynamics
7.8.9.2. Target Disease Prevalence
7.8.9.3. Competitive Scenario
7.8.9.4. Regulatory Framework
7.8.9.5. Sweden Market estimates and forecast, 2021 - 2033
7.8.10. Norway
7.8.10.1. Key Country Dynamics
7.8.10.2. Target Disease Prevalence
7.8.10.3. Competitive Scenario
7.8.10.4. Regulatory Framework
7.8.10.5. Norway Market estimates and forecast, 2021 - 2033
7.9. Asia Pacific
7.9.1. SWOT Analysis
7.9.2. Asia Pacific Market estimates and forecast, 2021 - 2033
7.9.3. China
7.9.3.1. Key Country Dynamics
7.9.3.2. Target Disease Prevalence
7.9.3.3. Competitive Scenario
7.9.3.4. Regulatory Framework
7.9.3.5. China Market estimates and forecast, 2021 - 2033
7.9.4. Japan
7.9.4.1. Key Country Dynamics
7.9.4.2. Target Disease Prevalence
7.9.4.3. Competitive Scenario
7.9.4.4. Regulatory Framework
7.9.4.5. Japan Market estimates and forecast, 2021 - 2033
7.9.5. India
7.9.5.1. Key Country Dynamics
7.9.5.2. Target Disease Prevalence
7.9.5.3. Competitive Scenario
7.9.5.4. Regulatory Framework
7.9.5.5. India Market estimates and forecast, 2021 - 2033
7.9.6. Australia
7.9.6.1. Key Country Dynamics
7.9.6.2. Target Disease Prevalence
7.9.6.3. Competitive Scenario
7.9.6.4. Regulatory Framework
7.9.6.5. Australia Market estimates and forecast, 2021 - 2033
7.9.7. Thailand
7.9.7.1. Key Country Dynamics
7.9.7.2. Target Disease Prevalence
7.9.7.3. Competitive Scenario
7.9.7.4. Regulatory Framework
7.9.7.5. Thailand Market estimates and forecast, 2021 - 2033
7.9.8. South Korea
7.9.8.1. Key Country Dynamics
7.9.8.2. Target Disease Prevalence
7.9.8.3. Competitive Scenario
7.9.8.4. Regulatory Framework
7.9.8.5. South Korea Market estimates and forecast, 2021 - 2033
7.10. Latin America
7.10.1. SWOT Analysis
7.10.2. Latin America Market estimates and forecast, 2021 - 2033
7.10.3. Brazil
7.10.3.1. Key Country Dynamics
7.10.3.2. Target Disease Prevalence
7.10.3.3. Competitive Scenario
7.10.3.4. Regulatory Framework
7.10.3.5. Brazil Market estimates and forecast, 2021 - 2033
7.10.4. Mexico
7.10.4.1. Key Country Dynamics
7.10.4.2. Target Disease Prevalence
7.10.4.3. Competitive Scenario
7.10.4.4. Regulatory Framework
7.10.4.5. Mexico Market estimates and forecast, 2021 - 2033
7.10.5. Argentina
7.10.5.1. Key Country Dynamics
7.10.5.2. Target Disease Prevalence
7.10.5.3. Competitive Scenario
7.10.5.4. Regulatory Framework
7.10.5.5. Argentina Market estimates and forecast, 2021 - 2033
7.11. MEA
7.11.1. SWOT Analysis
7.11.2. MEA Market estimates and forecast, 2021 - 2033
7.11.3. Saudi Arabia
7.11.3.1. Key Country Dynamics
7.11.3.2. Target Disease Prevalence
7.11.3.3. Competitive Scenario
7.11.3.4. Regulatory Framework
7.11.3.5. Saudi Arabia Market estimates and forecast, 2021 - 2033
7.11.4. South Africa
7.11.4.1. Key Country Dynamics
7.11.4.2. Target Disease Prevalence
7.11.4.3. Competitive Scenario
7.11.4.4. Regulatory Framework
7.11.4.5. South Africa Market estimates and forecast, 2021 - 2033
7.11.5. UAE
7.11.5.1. Key Country Dynamics
7.11.5.2. Target Disease Prevalence
7.11.5.3. Competitive Scenario
7.11.5.4. Regulatory Framework
7.11.5.5. UAE Market estimates and forecast, 2021 - 2033
7.11.6. Kuwait
7.11.6.1. Key Country Dynamics
7.11.6.2. Target Disease Prevalence
7.11.6.3. Competitive Scenario
7.11.6.4. Regulatory Framework
7.11.6.5. Kuwait Market estimates and forecast, 2021 - 2033
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Innovators
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2021
8.3.4. ECKERT & ZIEGLER BEBIG
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. ISORAY MEDICAL, INC.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. ELEKTA AB
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. THERAGENICS
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Becton, Dickinson, and Company
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. CIVCO MEDICAL SOLUTIONS
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. SUN NUCLEAR CORPORATION
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. ICAD, INC.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. VARIAN MEDICAL SYSTEMS, INC.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers